

1 Title: Vaccination saves lives: How do patients with chronic diseases and severe COVID-19 fare? Analysis
2 from India's National Clinical registry for COVID-19

3 Author List

4
5 ¶Aparna Mukherjee, PhD¹; ¶Gunjan Kumar, MD¹; Alka Turuk, MD¹; Ashish Bhalla, MD²; Thrilok
6 Chander Bingi, MD³; Pankaj Bhardwaj, MD⁴; Tridip Dutta Baruah, MS⁵; Subhasis Mukherjee, MD⁶;
7 Arunansu Talukdar, PhD⁷; Yogiraj Ray, MD⁸; Mary John, MD⁹; Janakkumar R Khambholja, MD¹⁰; Amit
8 H. Patel, MD¹¹; Sourin Bhuniya, MD¹²; Rajnish Joshi, MD¹³; Geetha R Menon, PhD¹⁴; Damodar Sahu,
9 PhD¹⁴; Vishnu Vardhan Rao, PhD¹⁴; Balram Bhargava, DM¹; *Samiran Panda, MD¹

10
11
12 And the NCRC Study team

13 Puspendra Mishra, MCA¹⁴; Yashmin Panchal, PGDISAD¹⁴; Lokesh Kumar Sharma, PhD¹; Anup Agarwal,
14 MBBS¹⁵; GD Puri, MD²; Vikas Suri, MD²; Karan Singla, MD²; Rajarao Mesipogu, MD³; Vinaya Sekhar
15 Aedula, MD³; Mohammed Ayaz Mohiuddin, MD³; Deepak Kumar, MD⁴; Suman Saurabh, MD⁴; Sanjeev
16 Misra, MCh⁴; Pankaj Kumar Kannauje, MD⁵; Ajit Kumar, MD⁵; Arvind Shukla, PhD⁵; Amitava Pal, MD⁶;
17 Shreetama Chakraborty, MSc⁶; Moumita Dutta, MSc⁶; Tanushree Mondal, MD⁷; Sarmistha Chakravorty,
18 MSc⁷; Boudhyan Bhattacharjee, MD⁷; Shekhar Ranjan Paul, DTC⁸; Debojyoti Majumder, MD⁸;
19 Subhanga Chatterjee, MBBS⁸; Abin Abraham, MD⁹; Divya Varghese, MD⁹; Maria Thomas, MD⁹; Nitesh
20 Shah, MD¹¹; Minesh Patel, MD¹¹; Surabhi Madan, MD¹¹; Anita Desai, PhD¹⁶; Kala Yadav M L, MD¹⁷;
21 Madhumathi. R, MD¹⁷; Chetna GS, MD¹⁷; U K Ojha, MD¹⁸; Ravi Ranjan Jha¹⁸; Avinash Kumar, MD¹⁸;
22 Ashish Pathak, PhD¹⁹; Ashish Sharma, MD¹⁹; Manju Purohit, MD¹⁹; Lisa Sarangi, MD²⁰; Mahesh Rath,
23 MD²⁰; Arti D. Shah, DNB²¹; Lavlesh Kumar, MD²¹; Princee Patel, MBBS²¹; Naveen Dulhani, MD²²;
24 Simmi Dube, MD²³; Jyotsna Shrivastava, MD²³; Arvind Mittal, MD²³; Lipilekha Patnaik, MD²⁴; Jagdish
25 Prasad Sahoo, DM²⁴; Sumita sharma²⁴; V K Katyal, MD, FACC²⁵; Ashima Katyal, MD²⁵; Nidhi Yadav,
26 MD²⁵; Rashmi Upadhyay, MD²⁶; Saurabh Srivastava, MD²⁶; Anurag Srivastava, MD²⁶; Nilay N.Suthar,
27 MD¹⁰; Nehal M. Shah, MD¹⁰; Kruti Rajvansh, MD¹⁰; Hemang Purohit, MSc¹⁰; Prasanta Raghav
28 Mohapatra, MD¹²; Manoj Kumar Panigrahi, MD¹²; Saurabh Saigal, MD, EDIC¹³; Alkesh Khurana, MD¹³;
29 Manisha Panchal, MD²⁷; Mayank Anderpa, MD²⁷; Dhruv Patel, MBBS²⁷; Veeresh Salgar, MD²⁸; Santosh
30 Algur, MBBS²⁸; Ratnamala Choudhury, MD²⁹; Mangala Rao, MD²⁹; Nithya D, MSc²⁹; Bal Kishan Gupta,
31 MD³⁰; Bhuvanesh Kumar, MD³⁰; Jigyasa Gupta, MBBS³⁰; Sudhir Bhandari, MD³¹; Abhishek Agrawal,
32 MD³¹; Mohammad Shameem, MD, FRCP³²; Nazish Fatima, MD³²; Star Pala, MD³³; Vijay Nongpiur,
33 DM³³; Soumyadip Chatterji, DM³⁴; Sudipta Mukherjee, FNB³⁴; Sachin K Shivnitwar, MD³⁵; Srikanth
34 Tripathy, MD³⁵; Prajakta Lokhande, MPH³⁵; Himanshu Dandu, MD³⁶; Amit Gupta, MD³⁶; Vivek Kumar,
35 MD³⁶; Nikita Sharma, MD³⁷; Rajat Vohra, MD³⁷; Archana Paliwal, MD³⁷; M.Pavan Kumar, MD³⁸;
36 A.Bikshapathi Rao, MD³⁸; Nyanthung Kikon, PGDPHM³⁹; Rhondemo Kikon, MScIH⁴⁰; K. Manohar,
37 MD⁴¹; Y.Sathyanarayana Raju, MD⁴¹; Arun Madharia, MS⁴²; Jaya Chakravarty, MD⁴³; Manaswi Chaubey,
38 MD⁴³; Rajiv Kumar Bandaru, MD⁴⁴; Mehdi Ali Mirza, DM⁴⁴; Sushila Kataria, MD⁴⁵; Pooja Sharma⁴⁵;
39 Soumitra Ghosh, MD⁴⁶; Avijit Hazra, MD⁴⁶.

40 ¹Indian Council of Medical Research, New Delhi, India

41 ² Postgraduate Institute of Medical Education & Research, Chandigarh, India

42 ³ Gandhi Medical College, Telangana, India

43 ⁴ All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India

44 ⁵ All Indian Institute of Medical Sciences, Raipur Chhattisgarh, India

45 ⁶ College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India

46 ⁷ Medical College, Kolkata, West Bengal, India

47 ⁸ Infectious Disease And Beliaghata Hospital, Kolkata, West Bengal, India

48 ⁹ Christian Medical College, Ludhiana, Punjab, India

49 ¹⁰ Smt. NHL, Municipal Medical College, Ahmedabad, Gujarat, India

50 ¹¹ CIMS Hospital, Ahmedabad, India

51 ¹² All India Institute Of Medical Sciences, Bhubaneswar, India

52 ¹³ All India Institute Of Medical Sciences, Bhopal, Madhya Pradesh, India

53 ¹⁴ National Institute of Medical Statistics, Indian Council of Medical Research, Delhi, India

54 ¹⁵ Medstar Health, Baltimore, Maryland, United States of America

55 ¹⁶ National Institute Of Mental Health And Neurosciences, Bangalore, Karnataka, India

56 ¹⁷ Dr. Yashwantrao Chavan Medical College & Research Institute, Bangalore, Karnataka, India

- 57 ¹⁸ Shaheed Nirmal Mahato Medical College, Dhanbad, Jharkahnd, India
58 ¹⁹ RD Gardi Medical College, Ujjain, Madhya Pradesh, India
59 ²⁰ Hi Tech Medical College and Hospital, Bhubaneswar, India
60 ²¹ Dhiraj Hospital & Sumandeep Vidyapeeth, Vadodara, Ahmedabad, India
61 ²² Late BRK Memorial Medical College, Jagdalpur, Chhattisgarh, India
62 ²³ Gandhi Medical College, Bhopal, Madhya Pradesh, India
63 ²⁴ Institute of Medical Sciences & SUM Hospital, Siksha ‘O’ Anusandhan deemed to be University,
64 Bhubaneswar, India
65 ²⁵ Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
66 ²⁶ Government Institute of Medical Sciences, Noida, Uttar Pradesh, India
67 ²⁷ GMERS Medical College Himmatnagar, Gujarat, India
68 ²⁸ Gulbarga Institute of Medical Sciences, Kalburagi, Karnataka, India
69 ²⁹ St. Johns Medical College, Bengaluru, Karnataka, India
70 ³⁰ S.P.Medical College, Bikaner, Rajasthan, India
71 ³¹ SMS Medical College, Jaipur, Rajasthan, India
72 ³² JN Medical College Aligarh Muslim University, Aligarh, Uttar Pradesh, India
73 ³³ North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya,
74 India
75 ³⁴ Tata Medical Centre, Kolkata, West Bengal, India
76 ³⁵ Dr D Y Patil Medical college Hospital and Research centre, Pune, Maharashtra, India
77 ³⁶ King George Medical University, Lucknow, Uttar Pradesh, India
78 ³⁷ Mahatma Gandhi Medical College, Jaipur, Rajasthan, India
79 ³⁸ Kakatiya Medical College, MGM Hospital Warangal, Telangana, India
80 ³⁹ Department of Health & Family Welfare, Government of Nagaland, Nagaland, India
81 ⁴⁰ Community Health Initiative, Nagaland, India
82 ⁴¹ Nizam’s Institute of Medical Sciences, Punjagutta, Hyderabad, India
83 ⁴² ESI Hospital and Gayatri Hospital, Raipur, Chhattisgarh, India
84 ⁴³ Institute of Medical sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
85 ⁴⁴ ESIC medical College, Sanathnagar, Hyderabad. India
86 ⁴⁵ Medanta-The Medicity, Gurugram, Haryana, India
87 ⁴⁶ Institute of Postgraduate Medical Education & Research, Kolkata, West Bengal

88
89

90 *Corresponding Author:
91 Dr. Samiran Panda
92 Email: samiranpanda.hq@icmr.gov.in

93

94 †These authors have contributed equally to this work.

95

96

97 This work was supported by the Indian Council of Medical Research

98

99

100

101

102

103

104

105

106

107

108

109 **Abstract**

110

111 Objectives: This study aims to describe the demographic and clinical profile and ascertain the
112 determinants of outcome among hospitalised COVID-19 adult patients enrolled in the National
113 Clinical Registry for COVID-19 (NCRC).

114

115 Methods: NCRC is an on-going data collection platform operational in 42 hospitals across India. Data
116 of hospitalized COVID-19 patients enrolled in NCRC between 1st September 2020 to 26th October
117 2021 were examined.

118

119 Results: Analysis of 29,509 hospitalised, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year;
120 male: 18752 (63.6%)] showed that 15678 (53.1%) had at least one comorbidity. Among 25715
121 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of
122 breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n=3957). Adjusted odds of
123 dying were significantly higher in age-group ≥ 60 years, males, with diabetes, chronic kidney diseases,
124 chronic liver disease, malignancy, and tuberculosis, presenting with dyspnea and neurological
125 symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95%
126 CI: 4.6, 7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4, 0.7)] or two doses of anti-SARS CoV-2
127 vaccine [OR: 0.4 (95% CI: 0.3, 0.7)] were protected from in-hospital mortality.

128

129 Conclusions: WHO ordinal scale at admission is the most important independent predictor for in-
130 hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection
131 against mortality.

132 Keywords: SARS-CoV2, mortality, risk factors, outcome, COVID-Vaccine

133

134 Figure 1: Comorbidity profile of patients, n=29509
135 HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus

136

137 Figure 2: Trends of selected drugs and oxygen requirements

138

139

140 **Introduction**

141 Globally, and in India, the pandemic of SARS-CoV-2 have resulted in unprecedented morbidity and
142 mortality with detrimental effect on healthcare systems and economies. As a response to the
143 pandemic, the ‘National Clinical Registry for COVID-19’ was initiated by the Indian Council of
144 Medical Research (ICMR) in September 2020, with a broad objective to collect good quality, real-
145 time data for evidence-based decision making in clinical practice, public health program and policy.

146
147 Hospital mortality among COVID-19 patients has varied from 19-39% across various studies.¹⁻⁶ It has
148 been observed that men, elderly (>60 years of age), and those with comorbidity such as asthma,
149 chronic obstructive pulmonary disease, tuberculosis, pneumonia, diabetes mellitus,
150 hypertension, renal, hepatic, and cardiac diseases and individuals with history of smoking or
151 substance use, history of kidney transplant are at higher risk of developing severe disease or
152 progression to death. The factors associated with such outcomes have been varied; older age being
153 consistent among many populations while others varied amongst studies.¹⁻⁸

154 Indian investigations have reported association of old age, presence of diabetes mellitus, presence of
155 severe acute respiratory infection, raised inflammatory markers including interleukin-6, ferritin,
156 lactate dehydrogenase and d-dimer with progression of COVID and/ or related in-hospital mortality⁹⁻
157 ¹². Majority of these studies enrolled a small number of participants located at a single centre. Here,
158 we present data from a large cohort of hospitalized COVID-19 patients from 42 hospitals across the
159 country.

160 The aim of this analysis is to study the demographic profile, clinical characteristics, and outcomes
161 among hospitalised COVID-19 adult patients, enrolled in the National Clinical Registry for COVID-
162 19 (NCRC) and to ascertain the factors associated with predefined outcomes.

163

164 **Methods**

165 The National Clinical Registry for COVID-19 (NCRC) is a platform for on-going prospective data
166 collection, developed and maintained by ICMR in collaboration with the Ministry of Health & Family
167 Welfare (MOHFW), Government of India, All India Institute of Medical Sciences, New Delhi
168 (AIIMS) and the ICMR-National Institute of Medical Statistics (NIMS). The structure and protocol of
169 the registry are available in the public domain (<https://www.icmr.gov.in/tab1ar1.html>). A hub and
170 spoke model has been adopted for this registry. At the beginning, an expression of intent was invited
171 for participation in the registry network; willing hospitals were screened based on a site feasibility
172 matrix. A steering committee with subject experts guides the conduct of the registry and suggests
173 solutions to roadblocks, if any. A monitoring committee consisting of institutional principal
174 investigators oversees the progress of the registry and explores newer ideas and initiatives, to keep the
175 registry dynamic. The central implementation team at ICMR headquarters remains responsible for the
176 overall execution of the project.

177 Across the network of NCRC, participating hospitals recruited consecutive in-patients, who had
178 COVID-19 infection confirmed by real time- polymerase chain reaction (RT-PCR), Nucleic acid
179 amplification test (NAAT) or Rapid Antigen Test (RAT). Demographic, clinical and outcome data are
180 collected in an on-going manner by the NCRC network. A dedicated team at the respective sites is
181 responsible for data collection and data entry under the supervision of the institutional primary
182 investigator and the central implementation team at ICMR. All the researchers were trained by the
183 central implementation team at ICMR via an online platform. Regular refresher trainings are
184 conducted in order to minimise errors, and to address the gaps created by change of personnel in the
185 teams.

186 Data is collected using a pre-structured case report form (CRF) and is entered into an electronic
187 portal, which has been developed and is being maintained by the ICMR-NIMS, Delhi. The CRFs
188 include socio-demographic information, symptom and comorbidity profile at the baseline, clinical
189 examination findings at the time of admission and on alternate days during the course of hospital stay,
190 results of laboratory investigations conducted as per treating physician and the outcomes of the
191 hospital stay.

192 The database platform is hosted on a secure server and is audited by the National Informatics Centre
193 (NIC). Information contained in the database, the configuration of the information within the
194 database, as well as the database itself are fully encrypted. Every client-server data transfer is
195 encrypted through a valid certificate. Data loss is prevented by frequent backup runs.

196 *Data Analysis*

197 Socio-demographic, clinical, laboratory and hospital outcome data were analysed; categorical data
198 presented as frequency and proportions and continuous data as mean (standard deviation) or median
199 (Inter-quartile range), as appropriate. Logistic regression model was used to determine the factors
200 associated with the outcome of the patients. For the purpose of outcome analysis, death was defined
201 as death due to any cause of a COVID-19 positive patient occurring during hospital stay. Patients who
202 were transferred to another hospital or left against medical advice were excluded from the outcome
203 analyses, though their baseline characteristics were analysed. Age, gender, body mass index, pre-
204 existing comorbidities, lag between symptom onset and admission, laboratory parameters at
205 admission including lactate dehydrogenase (LDH), ferritin, d-dimer, C-reactive protein (CRP) and
206 neutrophil to lymphocyte ratio (NLR), severity assessment by WHO ordinal scale¹³ and status of anti-
207 covid19 vaccination were used as explanatory variables in univariate analysis. Chi Square test, t-test
208 or rank sum test was used to examine the association between explanatory variables and outcome, as
209 appropriate. The variables with significant association and those with known clinical or contextual
210 importance were included in the multivariate logistic regression model. As laboratory values were

211 available for a limited number of participants, separate models were used for each of the biomarkers.
 212 Data analysis was carried out using STATA v14 (College Station, TX, US).

213 *Ethical Aspects*

214 Approval was obtained from the Central Ethics Committee for Human Research at ICMR as well as
 215 from the respective Institutional Ethics Committee of each of the participating centres. Considering
 216 the observational nature of the registry, and collection of anonymised data being done primarily from
 217 the routine case records of the patients, a waiver of consent was granted by the Ethics Committees.

218

219 **Results**

220 We present here an analysis of 29,509 hospitalised COVID-19 patients over the age of 18 years who
 221 were enrolled in NCRC from 1st September 2020 till 26th October 2021. The mean \pm SD age of the
 222 study population was 51.1 ± 16.2 years; men (51.1 ± 16 years) being similar to that of women ($51 \pm$
 223 16.5 years). Almost three fourth of the participants were at 40 years of age or above and two-thirds of
 224 the study participants in this group were men. The mean \pm SD body mass index of the participants
 225 was 24.8 ± 4.1 kg/m², with one-third of the participants being within normal range, while over 64%
 226 were obese or overweight. (Table 1) Four per cent of the enrolled study participants were health care
 227 workers.

228

229 Table 1: Demographic, symptom and laboratory profile at the time of admission (n=29509)

Characteristic	Values
Age groups 18-39 year 40-59 year 60 year and above	7742 (26.2) 11664 (39.5) 10103 (34.2)
Gender Male Female Transgender	18752 (63.6) 10754 (36.4) 3 (0.01)
Patients who had taken at least one dose of anti- SARS CoV-2 vaccine, n=7438	909 (12.2)
#BMI, kg/m ² , mean \pm SD, n=12046 Underweight Normal Overweight Obese	24.8 ± 4.1 361 (3) 3863 (32.1) 2765 (22.9) 5057 (42)
Symptom onset to admission in days, Median (IQR)	4 (2,6)
Total bilirubin, mg/dL Median (IQR), n=15091	0.6 (0.4, 0.8)
Hemoglobin, g/dL (Mean \pm SD), n= 18506	12.2 ± 2.2
WBC count (Cells /mm ³), Median (IQR), n=18171	7400 (5200, 11000)
Neutrophils, % , Median (IQR), n=16053	76.5 (65.5, 85)
Lymphocytes, % , Median (IQR), n= 15971	17 (10, 26.6)

Neutrophil to lymphocyte ratio (NLR), Median (IQR), n=15942	4.4 (2.5, 8.5)
Platelet count, 1000s/ml ³ Median (IQR), n=18089	212 (158, 278)
Ferritin, ng/mL, Median (IQR), n=7166	2059 (1019, 3192)
LDH, IU/L, Median (IQR), n=8515	400 (265, 649)
CRP, mg/dL, Median (IQR), n=9962	32 (7.7, 90.3)
IL-6, pg/mL Median (IQR), n=2192	17 (5.8, 53.3)
D-Dimer, mg/L, Median (IQR), n=8142	0.6 (0.3, 1.9)
WHO Ordinal scale ^{##} on day 1 of admission, n=26909	
• 3	13860 (51.5)
• 4	9864 (36.7)
• 5	2580 (9.6)
• 6	526 (2)
• 7	79 (0.3)

230 **Values expressed in n (%) unless specified.**

231 **#(Underweight: <18.5 kg/m², normal weight: 18.5-22.9 kg/m², overweight: 23-24.9 kg/m², obese: ≥25 kg/m²) Ref:**
 232 **WHO expert consultation group. Appropriate body-mass index for Asian populations and its implications for policy**
 233 **and intervention strategies. Lancet Public Health. 2004; 363 (9403):157-163.**
 234 **#[https://www.who.int/blueprint/priority-diseases/key-](https://www.who.int/blueprint/priority-diseases/key-action/COVID19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf)**
 235 **action/COVID19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf**

236

237 Of the 29509 patients enrolled, 3794 (12.9%) were asymptomatic at the time of admission and were
 238 admitted due to conditions other than COVID-19 and later diagnosed to have COVID-19 or
 239 developed COVID-19 during the course of hospitalisation. Among 25715 (87.1%) patients who were
 240 admitted with symptoms, fever was the most common symptom (72.3%). Shortness of breath and dry
 241 cough was recorded in 48.9% and 45.5% of patients, respectively. Some of the other symptoms were
 242 fatigue (20.7%), cough with sputum (14.5%), sore throat (13.5%), muscle ache (12.3%) and headache
 243 (11.2%). (S1 Figure)

244 Median haemoglobin, leucocytes count, neutrophils and lymphocytes were largely within normal
 245 limits while the inflammatory markers were raised. (Table 1)

246 No comorbidities were present in 13831 (46.9%) patients; 15678 (53.1%) participants had at least one
 247 comorbidity. Hypertension and diabetes mellitus were the commonest comorbidities reported among
 248 32.4% and 26.2% of patients, respectively. Chronic cardiac disease and chronic kidney disease was
 249 present among 5.7% and 3.6% of the study participants, respectively. Other diseases including
 250 asthma, malignancy, chronic pulmonary disease, chronic liver disease, stroke, tuberculosis, chronic
 251 neurological disease, rheumatologic disease, autoimmune disease, and haematological disorders, HIV
 252 infection, Hepatitis B and Hepatitis C infection were each reported in less than 2% of patients. (Figure
 253 1)

254 The most commonly used drugs were anticoagulants and steroids administered to 60.9% and 60% of
 255 patients, respectively. Doxycycline, ivermectin, remdesivir and azithromycin were the other

256 commonly used drugs, while hydroxychloroquine, oseltavimvir, faviparavir, IL-6 inhibitors including
 257 tocilizumab or itolizumab and convalescent plasma each was administered to less than 5% of patients.
 258 More than half of the admitted patients (15922, 54%) required oxygen support during their hospital
 259 course, while 2307 (7.8%) required mechanical ventilation. (S1 Table)

260 Figure 2 shows the monthly trend of selected therapies since the inception of the registry. A marked
 261 increase is noticeable in the use of steroid, oxygen supplementation and remdesivir in May 2021,
 262 coinciding with the 2nd wave of the pandemic in India dominated by the delta variant of SARS-CoV-
 263 2 infection. The use of hydroxychloroquine considerably declined after September 2020, while the use
 264 of convalescent plasma has been low throughout.

265 Outcome data on death or discharge were available for 27251 patients; 689 patients who left against
 266 medical advice and 1569 patients transferred to other hospitals were excluded from the outcome
 267 analysis. In-hospital deaths were reported in 3957 (14.5%) participants and 23294 (85.5%) were
 268 discharged. The median duration (IQR) of hospital stay among the study participants was 7 (5, 10)
 269 days; 7 (5, 10) days among those discharged and 6 (2, 10) days among those who expired (p =
 270 <0.001). Out of the 3957 patients who expired, 3418 (86.4%) died within first 14 days of hospital stay
 271 and 539 (13.6%) died after 14 days of hospital admission.

272 Table 2 shows the association of baseline factors with in-hospital mortality in univariate analysis. Age
 273 ≥ 40 year, male gender, comorbidities such as diabetes mellitus, hypertension, chronic cardiac
 274 disease, chronic kidney disease, chronic liver disease, malignancy, and stroke, tuberculosis well as
 275 respiratory (fast or difficult breathing) or neurological symptoms (altered sensorium or seizures) at
 276 presentation and WHO ordinal scale of 4 and above were associated with higher mortality. Receipt of
 277 at least one dose of anti- SARS CoV-2 vaccine was associated with lower mortality as compared to
 278 the unvaccinated patients [114 (13.3%) vs. 1306 (21.9%), p < 0.001]. Median concentrations of
 279 random blood sugar, NLR, LDH, Interleukin-6 (IL-6), CRP, and D-dimer were significantly higher
 280 among the patients who died as compared to those who were discharged from hospital. (Table 3)

281 Table 2: Proportional mortality among hospitalized COVID-19 patients
 282

Characteristic	Mortality (%)	Odds ratio (95% CI)	P value
Age			
• 18-39 years (n=7169)	529 (7.4)	(Reference)	-
• 40-59 years (n=10760)	1455 (13.5)	2 (1.8, 2.2)	<0.001
• 60+ years (n=9322)	1973 (21.2)	3.4 (3.0, 3.7)	<0.001
Gender			
• Male (n=17240)	2613 (15.2)	1.2 (1.1, 1.2)	<0.001
• Female (n=10008)	1344 (13.4)	(reference)	-
Vaccinated with Anti-SARS CoV-2 vaccine			
• Unvaccinated (n= 5964)	1306 (21.9)	(Reference)	
• Vaccinated with one dose (n=550)	85 (15.5)	0.7 (0.5, 0.8)	<0.001
• Vaccinated with two doses (n=305)	29 (9.5)	0.4 (0.3, 0.6)	<0.001
Diabetes Mellitus			
• Yes (n=7126)	1397 (19.6)	1.7 (1.6, 1.8)	<0.001

• No (n=20125)	2560 (12.7)	(Reference)	
Hypertension			
• Yes (n=8872)	1686 (19)	1.7 (1.6,1.8)	<0.001
• No (n=18379)	2272 (12.4)	(Reference)	
Chronic Cardiac Disease			
• Yes (n=1519)	296 (19.5)	1.5 (1.3,1.7)	<0.001
• No (n=25732)	3661 (14.2)		
Chronic Kidney Disease			
• Yes (n=934)	323 (34.6)	3.3 (2.9,3.8)	<0.001
• No (n=26317)	3634 (13.8)	(Reference)	
Chronic Liver Disease			
• Yes (n=250)	80 (32)	2.8 (2.1, 3.7)	<0.001
• No (n=27001)	3877 (14.4)	(Reference)	
Malignancy			
• Yes (n=413)	89 (21.6)	1.6 (1.3,2.1)	<0.001
• No (n=26838)	3868 (14.4)	(Reference)	
Stroke			
• Yes (n=190)	64 (33.7)	3.0 (2.2, 4.1)	<0.001
• No (n=27061)	3893 (14.4)	(Reference)	
Tuberculosis			
• Yes (n=169)	41 (24.3)	1.9 (1.3, 2.7)	<0.001
• No (n=27082)	3916 (14.5)	(reference)	
Shortness of breath or fast breathing at admission			
• Yes (n=11798)	2772 (23.5)	3.7 (3.4, 4.0)	<0.001
• No (n=15453)	1185 (7.7)	(Reference)	
Altered sensorium/ seizures at admission			
• Yes (n=412)	185 (44.9)	5.0 (4.1, 6.1)	<0.001
• No (n=26839)	3772 (14.1)	(Reference)	
Ordinal scale 4 or above at admission			
• Yes (n=13860)	3101 (26.3)	10.3 (9.2, 11.4)	<0.001
• No (n=13049)	433 (3.4)	(Reference)	
BMI			
• Underweight & normal (n= 3944)	387 (9.8)	(Reference)	-
• Overweight & obese (n= 7307)	766 (10.5)	1.1 (0.9, 1.2)	0.26

283 *P value calculated by bivariate logistic regression

284 Table 3: Median laboratory parameters among patients who died and those who survived

Laboratory Parameter	Median (IQR)	P Value
Hemoglobin Median (IQR), g/dL		
• Among those who died (n=2160)	12 (10.1, 13.4)	<0.001
• Among survivors (n=15098)	12.5 (11.1, 13.8)	
Random Blood Sugar, Median (IQR)		
• Among those who died (n=980)	180 (132, 255)	<0.001
• Among the survivors (n=7003)	138 (105, 228)	
Neutrophil lymphocyte Ratio Median (IQR)		
• Among those who died (n=1762)	10.7 (6.1, 19)	<0.001
• Among survivors (n=13156)	3.9 (2.3, 7.3)	
LDH Median (IQR), IU/L		
• Among those who died (n=1021)	690.6 (458, 959)	<0.001
• Among survivors (n=6962)	365 (248, 575)	
IL-6 Median (IQR), pg/mL		
• Among those who died (n=347)	59.2 (21, 180)	<0.001
• Among survivors (n=1711)	13 (4.7, 36.7)	
CRP Median (IQR), mg/dL		
• Among those who died (n=1231)	84.3 (39.6, 141.8)	<0.001
• Among survivors (n=8156)	25.1 (6.1, 78.6)	
D-Dimer Median (IQR), mg/L		
• Among those who died (n=1007)	1.6 (0.7, 5.9)	<0.001
• Among survivors (n=6658)	0.5 (0.3, 1.4)	
Symptom onset to admission		
• Among those who died (n=21382)	4 (2,6)	0.54
• Among survivors (n=3502)	4 (2,6)	

285 *p value calculated by rank sum test

286

287 On sub group analysis of patients with diabetes mellitus, malignancy, tuberculosis and those admitted
 288 with WHO ordinal scale 4 and above, mortality among vaccinated was significantly lower in each
 289 individual subgroup. Among patients with liver disease and kidney disease, though the mortality was
 290 lower among the vaccinated but the difference was not statistically significant (Not shown in table).

291 Factors that were significantly associated with mortality in univariate analysis and those which had
 292 clinical relevance were considered in the multivariate logistic models. Odds of in-hospital mortality
 293 was significantly and independently higher among patients ≥ 40 year, male gender, with diabetes
 294 mellitus, chronic kidney diseases, chronic liver disease, malignancy, and tuberculosis, and those who
 295 presented with dyspnoea or neurological symptoms, after being adjusted for other comorbidities such
 296 as hypertension, chronic cardiac disease, stroke, severity at admission (WHO ordinal scale), and
 297 vaccination status. WHO ordinal scale being 4 and above at admission carried the highest odds of
 298 dying [5.6 (95% CI: 4.6, 7.0)]. Patients vaccinated with one and two doses of anti-SARS CoV-2
 299 vaccine had significantly lower odds of dying [OR: 0.5 (95% CI: 0.4, 0.7) for one dose & OR: 0.4
 300 (95% CI: 0.3, 0.7) for two doses]. (Table 4)

301

302 Table 4: Adjusted Hazards ratio Determinants of hospital deaths using logistic regression
 303

	Model 1 (n=6159)
	Odds ratio (95% CI)
Age Categories	(Reference)
• 18-39 years	1.3 (1.1, 1.6)
• 40-59 years	1.9 (1.6, 2.3)
• 60 years and above	
Gender (Male)	1.3 (1.1, 1.5)
Vaccinated with Anti-SARS CoV-2 vaccine	
• One dose	0.5 (0.4, 0.7)
• Two doses	0.4 (0.3, 0.7)
Diabetes Mellitus	1.4 (1.2, 1.6)
Hypertension	0.9 (0.8, 1.1)
Chronic Cardiac Disease	0.8 (0.6, 1.0)
Chronic Kidney Disease	2.8 (2.0, 3.7)
Chronic Liver Disease	2.4 (1.1, 5.2)
Malignancy	1.9 (1.2, 3.2)
Stroke	1.0 (0.5, 2.3)
Tuberculosis	3.0 (1.5, 6.1)
Shortness of breath or fast breathing	1.3 (1.1, 1.5)
Altered sensorium/ seizures	3.6 (2.4, 5.4)
WHO ordinal scale 4 and above at admission	5.6 (4.6, 7.0)

304

305 Data available for various baseline laboratory parameters at baseline were limited (as described in
 306 table 3). Hence, separate models were tested for each of these parameters. The odds ratio for all
 307 biomarkers including haemoglobin, LDH, IL-6, and CRP were statistically significant, but marginally
 308 over 1. The odds of death increased by 1.1 for each unit rise in baseline values of NLR and D-dimer

309 separately [OR:1.1 95%CI: 1.1,1.1] after adjusting for age, comorbidities and severity of the illness at
310 admission. The logistic regression models (Model 2 to 8) that included laboratory values are
311 presented as S2 Table. The area under the curve for ROC (AUC ROC) for NLR was 0.79 (95%CI:
312 0.78, 0.80) and 0.7 (0.68, 0.71). (S2 Figure) Considering the optimal cut-off for NLR as 6.67, both the
313 sensitivity and specificity to classify in-hospital death was 72%; a cut-off of 0.82 mg/L for baseline
314 D-Dimer had a sensitivity and specificity 71% and 65%, respectively.

315

316 **Discussion**

317 Our study includes data from 29509 hospitalised COVID-19 patients from 42 hospitals across the
318 country. Apart from the often cited factors such as diabetes mellitus, male gender and advanced age,
319 our study highlighted the association of other comorbidities such as chronic kidney disease, chronic
320 liver disease, malignancy and tuberculosis with increased in-hospital mortality of COVID-19 patients
321 in Indian settings. The importance of anti-SARS-CoV-2 vaccination in protecting against mortality
322 was also evident from our analysis.

323 More than half of our study participants had at least one co-morbidity, most common being
324 hypertension & diabetes mellitus. The proportion of COVID-19 in-patients having hypertension is
325 similar to the overall population level frequency of hypertension recorded among adult Indians. On
326 the contrary proportion diabetics seem to be much higher in this cohort than the national
327 average.^{13,14,15} Multiple studies have confirmed that following SARS-CoV-2 infection, diabetics are
328 more likely to be hospitalised as compared to non-diabetics, especially if there is poor glycaemic
329 control.¹⁶ Diabetes causes an inhibition in neutrophil chemotaxis, phagocytosis, and intracellular
330 destruction of microbes, thus offering efficient virus entry and decreased viral clearance.¹⁷

331 In our study, patients above 40 years of age had 1.3 times higher adjusted odds of dying than the
332 younger patients, which increased to 2.1 time with advanced age ≥ 60 year. Advanced age, especially
333 ≥ 60 year, is an established independent risk factor for dying in COVID-19 patients, as shown in
334 various studies across multiple countries since the onset of the pandemic.^{18,15} However, the working
335 age population above 40 years of age also have been deeply affected as shown in our investigation. It
336 would be prudent to include them in all preventive measures and triaging strategies for severity. Age-
337 standardized mortalities for COVID-19 in India, analysed from the Integrated Disease Surveillance
338 Programme special surveillance data, showed that along with the elderly above 60 years of age, the
339 age group of 45-59 years were also affected.²⁰ This could be partly explained by the fact that forced
340 expiratory volume is generally seen to decline after the age of 30-40 years.²¹ Additionally, older age
341 group is known to have a higher prevalence of chronic diseases, which could further attenuate the
342 already dysregulated immune response.

343 Studies from various parts of India and the world have reported co-morbidities in various
344 combinations to be associated with in-patient mortality in COVID-19 patients.^{16,17,24,25,26} Along with
345 the more recognized risk factors such as diabetes mellitus, chronic kidney disease, and malignancy,

346 our investigation unearthed the independent association of chronic liver disease with higher odds of
347 dying among COVID-19 in-patients. Another retrospective analysis from a single centre in South
348 India linked chronic liver disease with in-hospital mortality of Covid-19 patients.²⁷ Increased systemic
349 inflammation, immune dysfunction, coagulopathy and intestine dysbiosis are the hypothesised
350 mechanisms. Important to note in this context is that, the pandemic has been associated with poor
351 eating habits and increased alcohol intake, which might lead to an increase in severity of liver
352 diseases.^{8,18,19,29}

353 Presence of tuberculosis (on-treatment TB) was an important factor associated with higher in-hospital
354 mortality in our cohort. This finding carries a significant relevance in a high TB burden country like
355 India. Increased severity and mortality have been reported in COVID-19 patients with tuberculosis in
356 two meta-analyses which included only 26 and 34 Indian patients, respectively ^{30,20}. Our study provides
357 more robust supportive evidence for association of present tuberculosis status with COVID-19
358 mortality.

359 Severity of illness at admission as evident by presenting complaints of respiratory or neurological
360 symptoms and WHO ordinal scale 4 or above had higher odds of dying in our registry participants.
361 Similar observations have been reported from a few single centre studies from India, where majority
362 of non-survivors required early oxygen supplementation (oxygen requirement is at WHO ordinal scale
363 4 and above)^{22,23}.

364 The baseline laboratory markers including neutrophil-lymphocyte ratio (NLR), LDH, D-Dimer, IL-6
365 and CRP were higher among the non-survivors, though on multivariate analysis, the odds ratio was
366 marginally above one with minimal clinical relevance, except for NLR and D-dimer. Previous studies
367 have shown that raised biomarkers such as IL-6, CRP, LDH, and NLR are associated with higher
368 mortality.³²⁻³⁵ Considering these markers are non-specific indicators of inflammation, the baseline
369 values of IL-6, CRP or LDH seem to offer limited benefit in meaningful prediction of mortality. NLR
370 being a readily available marker can be used to prognosticate outcomes at admission as can D-Dimer.
371 However, guidelines for clinical management from other countries have also stated that there is no
372 consensus in the evidence supporting use of any of the inflammatory markers or D-dimer at baseline
373 to stratify the risk and decide therapeutics.³⁶

374 Importantly, the current study underlined the protection provided by COVID-19 vaccination against
375 in-hospital mortality. COVID-19 vaccine, irrespective its type, reduced the odds of dying by 50%
376 with one dose and by 60% with two doses. Other smaller, single centre studies from both South and
377 North India have demonstrated the effectiveness of COVID-19 vaccination in reducing mortality.^{37,38}
378 These findings along with mathematical modelling based projections³⁹ underscore the key role of
379 vaccine in mitigating the impact of COVID pandemic and managing the burden it poses on the
380 healthcare system.

381

382

383 *Limitations*

384 As this was a record-based study in hospitals maintaining paper-based records, the identification of
385 symptoms, comorbidities, complications and laboratory parameters relied on the accuracy of the
386 records maintained. Secondly, the patients who were transferred to other institutes or who had left
387 against medical advice were not followed up and could not be included in mortality analysis as their
388 outcomes were unknown.

389

390 *Strengths*

391 The current analysis from the National Clinical Registry for COVID-19, to the best of our knowledge,
392 is the largest widely representative to examine the association of demographic, clinical characteristics,
393 and laboratory parameters with mortality among hospitalised COVID-19 patients in India. This data
394 captures information from various geographical zones of India involving multiple centres.

395

396 **Conclusion**

397 The current investigation highlights the importance of age ≥ 40 years and comorbidities like chronic
398 liver disease, and tuberculosis as predictors of in-patient mortality along with the oft-reported risk
399 factors such as male gender, diabetes mellitus, chronic kidney disease, and baseline severity of illness.
400 WHO ordinal scale 4 and above was an important independent factor associated with in-patient
401 mortality. Interestingly, the baseline values of CRP, IL-6 and LDH offered little help in predicting the
402 outcome, though NLR and D-dimer can be used to classify in-hospital outcomes with a sensitivity and
403 specificity ranging from 65% to 72%. On an encouraging note, vaccination against COVID-19
404 clearly lowered the risk of dying from the disease and featured as an important armamentarium in our
405 fight against COVID-19 pandemic.

406

407

408

409

410

411

412

413

414

415

416 Author statements

417

418 Author Contributions

419

420 SP is the guarantor. Study design, data analysis, data interpretation and manuscript writing team: AM, GK, AT,
421 AB, TCB, PB, TDB, SM, AT, YR, MJ, JRK, AHP, SB, RJ, GRM, DS, VVR, BB, SP, AA. Monitoring and
422 Conduct of the study: AM, GK, AT, LKS, PM, YP. Patient enrolment, conduct of study, clinical care and data
423 collection: AB, TCB, PB, TDB, SM, AT, YR, MJ, JRK, AHP, SB, RJ, GDP, VS, KS, RM, VSA, MAM, DK,
424 SS, SM, PKK, AK, AS, AP, SC, MD, TM, SC, BB, SRP, DM, SC, AA, DV, MT, NS, MP, SM, AD, KYL, MR,
425 CGS, UKO, RRJ, AK, AP, AS, MP, LS, MR, ADS, LK, PP, ND, SD, JS, AM, LP, JPS, SS, VKK, AK, NY,
426 RU, SS, AS, NNS, NMS, KR, HP, PRM, MKP, SS, AK, MP, MA, DP, VS, SA, RC, MR, ND, BKG, BK, JG,
427 SB, AA, MS, NF, SP, VN, SC, SM, SKS, ST, PL, HD, AG, VK, NS, RV, AP, MPK, ABR, NK, RK, KM, YSR,
428 AM, JC, MC, RKB, MAM, SK, PS, SG, AH.

429

430 Sources of Funding

431 The study was supported by the Indian Council of Medical Research, New Delhi.

432

433 Conflict of interest disclosure

434 AM, GK, AT, LKS, SP are employed by the Indian Council of Medical Research, the funding source of the
435 study. AA was employed by the Indian Council of Medical research at the beginning of the study.

436 No other author has declared any conflict of interest.

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453 Bibliography

- 454 1. Becerra-Muñoz VM, Núñez-Gil IJ, Eid CM, García Aguado M, Romero R, Huang J, et al.
455 Clinical profile and predictors of in-hospital mortality among older patients hospitalised for
456 COVID-19. *Age Ageing*. 2021 Feb 26;50(2):326–34.
- 457 2. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital
458 Mortality in a US National Sample of Patients With COVID-19. *JAMA Netw Open*. 2020 Dec
459 1;3(12):e2029058.
- 460 3. Gray WK, Navaratnam AV, Day J, Babu P, Mackinnon S, Adelaja I, et al. Variability in
461 COVID-19 in-hospital mortality rates between national health service trusts and regions in
462 England: A national observational study for the Getting It Right First Time Programme.
463 *EClinicalMedicine*. 2021 May;35:100859.
- 464 4. Khamis F, Memish Z, Bahrani MA, Dowaiqi SA, Pandak N, Bolushi ZA, et al. Prevalence and
465 predictors of in-hospital mortality of patients hospitalized with COVID-19 infection. *J Infect
466 Public Health*. 2021 Jun;14(6):759–65.
- 467 5. Ruscica M, Macchi C, Iodice S, Tersalvi G, Rota I, Ghidini S, et al. Prognostic parameters of in-
468 hospital mortality in COVID-19 patients—An Italian experience. *Eur J Clin Invest*. 2021
469 Sep;51(9).
- 470 6. Sarfaraz S, Shaikh Q, Saleem SG, Rahim A, Herekar FF, Junejo S, et al. (2021) Determinants of
471 in-hospital mortality in COVID-19; a prospective cohort study from Pakistan. *PLoS ONE* 16(5):
472 e0251754. <https://doi.org/10.1371/journal.pone.0251754>.
- 473 7. Galiero R, Pafundi PC, Simeon V, Rinaldi L, Perrella A, Vetrano E, et al. Impact of chronic
474 liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA
475 study. *PloS One*. 2020;15(12):e0243700.
- 476 8. Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of
477 30-day mortality in patients with cirrhosis and COVID-19. *J Hepatol*. 2020 Nov;73(5):1063–71.
- 478 9. Mammen JJ, Kumar S, Thomas L, Kumar G, Zachariah A, Jeyaseelan L, et al. Factors
479 associated with mortality among moderate and severe patients with COVID-19 in India: a
480 secondary analysis of a randomised controlled trial. *BMJ Open*. 2021 Oct 4;11(10):e050571.
- 481 10. Zodpey SP, Negandhi H, Kamal VK, Bhatnagar T, Ganeshkumar P, Athavale A, et al. (2021)
482 Determinants of severity among hospitalised COVID-19 patients: Hospital-based case-control
483 study, India, 2020. *PLoS ONE* 16(12): e0261529. <https://doi.org/10.1371/journal.pone.0261529>.

- 484 11. Agarwal. Epidemiological determinants of COVID-19 infection and mortality: A study among
485 patients presenting with severe acute respiratory illness during the pandemic in Bihar, India
486 [Internet]. [cited 2022 Jan 17]. Available from: [https://www.npmj.org/article.asp?issn=1117-
487 1936;year=2020;volume=27;issue=4;spage=293;epage=301;aulast=Agarwal](https://www.npmj.org/article.asp?issn=1117-1936;year=2020;volume=27;issue=4;spage=293;epage=301;aulast=Agarwal)
- 488 12. Mishra V, Burma AD, Das SK, Parivallal MB, Amudhan S, Rao GN. COVID-19-Hospitalized
489 Patients in Karnataka: Survival and Stay Characteristics. *Indian J Public Health*. 2020
490 Jun;64(Supplement):S221–4.
- 491 13. Ramakrishnan S, Zachariah G, Gupta K, Shivkumar Rao J, Mohanan PP, Venugopal K, et al.
492 Prevalence of hypertension among Indian adults: Results from the great India blood pressure
493 survey. *Indian Heart J*. 2019 Jul 1;71(4):309–13.
- 494 14. Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes
495 and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-
496 sectional study. *Lancet Diabetes Endocrinol*. 2017 Aug;5(8):585–96.
- 497 15. O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al.
498 Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*. 2021
499 Feb;590(7844):140–5.
- 500 16. Barman Roy D, Gupta V, Tomar S, Gupta G, Biswas A, Ranjan P, et al. Epidemiology and Risk
501 Factors of COVID-19-Related Mortality. *Cureus*. 13(12):e20072.
- 502 17. Padmaprakash KV, Vardhan V, Thareja S, Muthukrishnan J, Raman N, Ashta KK, et al.
503 Clinical characteristics and clinical predictors of mortality in hospitalised patients of COVID
504 19 : An Indian study. *Med J Armed Forces India*. 2021 Jul;77(Suppl 2):S319–32.
- 505 18. Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic
506 liver disease in the United States. *EClinicalMedicine*. 2020 Dec 22;31:100688.
- 507 19. Marjot T, Webb GJ, Barritt AS, Moon AM, Stamataki Z, Wong VW, et al. COVID-19 and liver
508 disease: mechanistic and clinical perspectives. *Nat Rev Gastroenterol Hepatol*. 2021 Mar 10;1–
509 17.
- 510 20. Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between tuberculosis and COVID-19
511 severity and mortality: A rapid systematic review and meta-analysis. *J Med Virol*. 2020 Jul
512 28;10.1002/jmv.26311.

513
514

515 S1 Figure: Clinical characteristics of the study subjects at the baseline among the symptomatic
516 patients, n=25715
517 S2aFigure: ROC for baseline neutrophil-lymphocyte ratio classifying in-hospital outcomes.
518 S2bFigure: ROC for baseline D-Dimer levels classifying in-hospital outcomes.
519 S1 Table: Treatment profile during hospital stay, n=29509
520 S2 Table: Adjusted odds ratio for determinants of hospital deaths among hospitalised COVID-19
521 patients using logistic regression model
522 S1 File: supplement
523
524
525
526




Figure 1




Figure 2